HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Electrocardiographic measurement of infarct size after thrombolytic therapy.

AbstractOBJECTIVES:
We examined the utility of the 32-point QRS score from the 12-lead electrocardiogram (ECG) for measurement of the ischemic risk region and infarct size in patients receiving thrombolytic therapy.
BACKGROUND:
The QRS score offers a means of evaluating the therapeutic benefit of thrombolytic therapy by comparing final infarct size with the initial extent of ischemic myocardium.
METHODS:
The study included 38 patients (34 men, 4 women; mean [+/-SD] age 54 +/- 10 years) with a first infarction (18 anterior, 20 inferior). The maximal potential QRS score (QRS0) was assigned to all leads with >/= 100-microV ST elevation on the initial ECG. The QRS scores were calculated at 7 and 30 days after infarction. Left ventricular ejection fraction was measured by radionuclide ventriculography at 1 month. Twenty-eight patients had thallium (Tl)-201 and technetium (Tc)-99m pyrophosphate tomographic measurement of the ischemic region and infarct size.
RESULTS:
The QRS0 was 10.3 +/- 3.1 (mean +/- SD) for anterior and 10.4 +/- 3.5 for inferior infarcts. The QRS scores were similar at 7 and 30 days for both anterior (5.6 +/- 3.4 vs. 5.5 +/- 3.4) and inferior infarcts (3.7 +/- 2.6 vs. 2.9 +/- 2.2). The day 7 QRS score and ejection fraction at 1 month were inversely correlated (r = -0.74, p < 0.01). The Tl-201 perfusion defect was 34 +/- 11% of the left ventricle for anterior and 32 +/- 7% for inferior infarcts. Subsequent Tc-99m pyrophosphate infarct size was 15 +/- 9% of the left ventricle for anterior and 17 +/- 9% for inferior infarcts. The QRS0 was correlated with the extent of the Tl-201 perfusion defect (r = 0.79, p < 0.001), and the day 7 QRS score was correlated with Tc-99m pyrophosphate infarct size (r = 0.79, p < 0.005).
CONCLUSIONS:
The 32-point QRS score can provide useful immediate measurements of the ischemic risk region and subsequent infarct size.
AuthorsC P Juergens, C Fernandes, E T Hasche, S Meikle, G Bautovich, C A Currie, S B Freedman, R W Jeremy
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 27 Issue 3 Pg. 617-24 (Mar 01 1996) ISSN: 0735-1097 [Print] United States
PMID8606273 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Topics
  • Aged
  • Drug Monitoring
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (diagnosis, drug therapy)
  • Prognosis
  • Prospective Studies
  • Radionuclide Ventriculography
  • Reproducibility of Results
  • Risk Factors
  • Severity of Illness Index
  • Stroke Volume
  • Thrombolytic Therapy
  • Time Factors
  • Tomography, Emission-Computed, Single-Photon

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: